Edgar Filing: MANNKIND CORP - Form 8-K

MANNKIND CORP Form 8-K February 09, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2015

MannKind Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of

000-50865 (Commission

13-3607736 (IRS Employer

incorporation or organization)

File Number)

Identification No.)

28903 North Avenue Paine

91355

Edgar Filing: MANNKIND CORP - Form 8-K

Valencia, California (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (661) 775-5300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))

Item 8.01 Other Events.

As previously announced by us and Sanofi in a joint press release on February 3, 2015, AFREZZA® is now available by prescription in United States retail pharmacies. AFREZZA, our only approved product, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration on June 27, 2014 to improve glycemic control in adult patients with diabetes.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 9, 2015

MANNKIND CORPORATION

By:/s/ David Thomson

Name: David Thomson, Ph.D., J.D.

Title: Corporate Vice President, General Counsel and

Secretary